CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 3, 2025, to holders of record on October 23, 2025. https://mma.prnewswire.com/media/487051/CVS_Health_Logo.jpg About CVS HealthCVS Health is a […]
— First-ever clinical data supporting safety and efficacy of invivo CAR-T Therapy in refractory systemic lupus erythematosus(SLE) patients. — Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of circulating B cells and up to 20-points reduction in patient's SLEDAI
NEW YORK, NY / ACCESS Newswire / September 17, 2025 / If you suffered a loss on your Nutex Health Inc. (NASDAQ:NUTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nutex-health-inc-lawsuit-submission-form?prid=167963&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / September 17, 2025 / If you suffered a loss on your Tronox Holdings plc (NYSE:TROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tronox-holdings-plc-lawsuit-submission-form?prid=167965&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
23rd Consecutive Quarter of a Consistent Dividend Trinity Capital Inc.(Nasdaq: TRIN) (“Trinity Capital” or “the Company”), a leading alternative asset manager, today announced that its Board of Directors declared a cash dividend of $0.51 per share with respect to the quarter ending September 30, 2025. This is an equivalent dividend compared to the second quarter
NEW YORK, NY / ACCESS Newswire / September 17, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CTO Realty Growth, Inc. (NYSE:CTO, CTO-PA) between February 18, 2021 and June 24, 2025, both dates inclusive (the "Class Period"), of the October 7, 2025 lead plaintiff deadline. SO
(Copenhagen:NOVO B), Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy(R)) achieved significant weight loss, with one in three study participants losing 20% or more body weight1** Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular
Novo Nordisk's oral semaglutide 25 mg (Wegovy(R) in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study GlobeNewswire September 17, 2025 Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy(R)) achieved significant weight loss, with one in three study participants losing 20% or more body weight1** Oral semaglutide
Silicon Valley Certification Hub Records 30% QoQ Revenue Growth as Demand for AI Certification Accelerates Silicon Valley Certification Hub achieved 30% quarter-over-quarter revenue growth as small and mid-sized firms seek official certification to prove they are AI-ready GlobeNewswire September 17, 2025 Photo Courtesy of: Silicon Valley Certification Hub. SILICON VALLEY, Calif., Sept. 17, 2025 (GLOBE
(NYSE:AGL), NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has continued its investigation into agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL). On January 5,